202 related articles for article (PubMed ID: 20371696)
1. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
Koyanagi K; O'Day SJ; Boasberg P; Atkins MB; Wang HJ; Gonzalez R; Lewis K; Thompson JA; Anderson CM; Lutzky J; Amatruda TT; Hersh E; Richards J; Weber JS; Hoon DS
Clin Cancer Res; 2010 Apr; 16(8):2402-8. PubMed ID: 20371696
[TBL] [Abstract][Full Text] [Related]
2. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
[TBL] [Abstract][Full Text] [Related]
3. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.
Hoshimoto S; Shingai T; Morton DL; Kuo C; Faries MB; Chong K; Elashoff D; Wang HJ; Elashoff RM; Hoon DS
J Clin Oncol; 2012 Nov; 30(31):3819-26. PubMed ID: 23008288
[TBL] [Abstract][Full Text] [Related]
4. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.
Hoshimoto S; Faries MB; Morton DL; Shingai T; Kuo C; Wang HJ; Elashoff R; Mozzillo N; Kelley MC; Thompson JF; Lee JE; Hoon DS
Ann Surg; 2012 Feb; 255(2):357-62. PubMed ID: 22202581
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients.
Kiyohara E; Hata K; Lam S; Hoon DS
Methods Mol Biol; 2014; 1102():513-22. PubMed ID: 24258996
[TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
7. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Kuo C; Wang HJ; Milford R; Morton DL; Hoon DS
Clin Cancer Res; 2006 Feb; 12(4):1137-43. PubMed ID: 16489066
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon.
Gogas H; Kefala G; Bafaloukos D; Frangia K; Polyzos A; Pectasides D; Tsoutsos D; Panagiotou P; Ioannovich J; Loukopoulos D
Br J Cancer; 2002 Jul; 87(2):181-6. PubMed ID: 12107840
[TBL] [Abstract][Full Text] [Related]
9. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.
Koyanagi K; Kuo C; Nakagawa T; Mori T; Ueno H; Lorico AR; Wang HJ; Hseuh E; O'Day SJ; Hoon DS
Clin Chem; 2005 Jun; 51(6):981-8. PubMed ID: 15817820
[TBL] [Abstract][Full Text] [Related]
10. Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma.
Schmidt H; Sørensen BS; von der Maase H; Bang C; Agger R; Hokland M; Nexo E
Melanoma Res; 2002 Dec; 12(6):585-92. PubMed ID: 12459648
[TBL] [Abstract][Full Text] [Related]
11. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
Koyanagi K; Mori T; O'Day SJ; Martinez SR; Wang HJ; Hoon DS
Cancer Res; 2006 Jun; 66(12):6111-7. PubMed ID: 16778184
[TBL] [Abstract][Full Text] [Related]
12. High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China.
Li J; Fu W; Zhang W; Li P
Med Sci Monit; 2018 Jan; 24():324-331. PubMed ID: 29337932
[TBL] [Abstract][Full Text] [Related]
13. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma.
Klinac D; Gray ES; Freeman JB; Reid A; Bowyer S; Millward M; Ziman M
BMC Cancer; 2014 Jun; 14():423. PubMed ID: 24915896
[TBL] [Abstract][Full Text] [Related]
14. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
Shinozaki M; O'Day SJ; Kitago M; Amersi F; Kuo C; Kim J; Wang HJ; Hoon DS
Clin Cancer Res; 2007 Apr; 13(7):2068-74. PubMed ID: 17404088
[TBL] [Abstract][Full Text] [Related]
15. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
[TBL] [Abstract][Full Text] [Related]
17. Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
Lin SY; Chang SC; Lam S; Irene Ramos R; Tran K; Ohe S; Salomon MP; Bhagat AAS; Teck Lim C; Fischer TD; Foshag LJ; Boley CL; O'Day SJ; Hoon DSB
Clin Chem; 2020 Jan; 66(1):169-177. PubMed ID: 31672856
[TBL] [Abstract][Full Text] [Related]
18. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
[TBL] [Abstract][Full Text] [Related]
19. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.
Reid AL; Millward M; Pearce R; Lee M; Frank MH; Ireland A; Monshizadeh L; Rai T; Heenan P; Medic S; Kumarasinghe P; Ziman M
Br J Dermatol; 2013 Jan; 168(1):85-92. PubMed ID: 23013138
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
Atkins MB; Hsu J; Lee S; Cohen GI; Flaherty LE; Sosman JA; Sondak VK; Kirkwood JM;
J Clin Oncol; 2008 Dec; 26(35):5748-54. PubMed ID: 19001327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
